Teva Close To A Deal For Allergan's Generic-Drugs Unit: Source

Teva Pharmaceutical Industries Ltd. is in advanced talks to buy Allergan PLC's generic-drug business in the midst of a thus-far-unsuccessful effort to acquire peer Mylan NV, according to a person familiar with the matter. Jerusalem-based Teva, which has offered to buy Mylan for $40 billion, is now close to an agreement to acquire Dublin-based Allergan's generic-drugs unit for between $40 billion and $45 billion, the person said.